Lead Product(s) : Loxicodegol
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Nektar Issues Statement Regarding FDA Advisory Committee Vote for Oxycodegol
Details : The FDA's Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee does not recommend NDA approval of Nektar's oxycodegol.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Not Applicable
January 14, 2020
Lead Product(s) : Loxicodegol
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Reset All
